Azeria Therapeutics is a Cambridge, UK-based drug discovery company founded in 2017. It is a pioneer factor oncology company developing treatments for hormone resistant breast cancer patients, based on the work of Professor Jason Carroll at the Cancer Research UK Cambridge Institute. The company is developing programmes that target FOXA1, an essential pioneer factor shown to be pivotal in tumour growth, progression and maintenance of oestrogen receptor positive luminal breast cancer. Extensive target validation and drug discovery work to date supports its lead program. Azeria plans to take the lead program into the clinic over the course of the Series B funding and to develop the program toward commercialization while exploring a pipeline of further oncology programmes. The company is led by CEO Stephen Myatt and recently completed a Series B financing to support these plans. Azeria Therapeutics is a spinout from Sixth Element Capital and Cancer Research UK’s commercial partnerships team that uses a proprietary drug screening platform to develop a pipeline of small molecules. The company is focused on selectively inhibiting pioneer transcription factors, initially targeting FOXA1, which is implicated in ER-positive luminal breast cancer and thought to be critical in prostate cancer. Its scientific work is based on discoveries from Dr Jason Carroll’s lab at the Cancer Research UK Cambridge Institute. Leadership includes CEO Stephen Myatt (also a partner at Sixth Element Capital) and founder/CSO Dr Jason Carroll. Azeria plans to continue preclinical development of its molecules aimed at hormone-resistant breast and prostate cancers. The company raised funding to advance its discovery programs and further validate its screening-derived candidates. Financially, Azeria completed a £4M Series A to support these activities.

Total raised

$47M

Funding rounds

2

Latest round

Series B

Latest activity

Nov 2019